Oral Cryotherapy Applied to Patients Undergoing Chemotherapy
Examining the Effect of Oral Cryotherapy Applied to Patients Undergoing Chemotherapy on Taste Change, Appetite Level, Malnutrition Risk and Quality of Life
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Rize, Turkey, 53100
- Recep Tayyip Erdogan University Training and Research Hospital
-
Rize, Turkey, 53100
- Recep Tayyip Erdogan University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Those receiving treatment in an outpatient chemotherapy unit,
- Able to communicate verbally,
- Literate,
- Eastern Cooperative Oncology Group (ECOG) Performance Score of two or below,
- Knowing their diagnosis,
- Taking five chemotherapeutic agents that cause taste changes, either alone or in combination (cisplatin, docetaxel, paclitaxel, oxaliplatin, vincristine),
- Verbally stating that they experience taste changes,
- Not smoking or quitting alcohol,
- Not using statins, hypothyroidism, antidiabetic, antipsychotic, hyperthyroidism, antidepressant, antihistamine, anti-inflammatory, antibiotic and antifungal drugs,
- Not having Chronic Renal Failure (CKD), metabolic (diabetes, thyroid disease, etc.) and liver (hepatitis, cirrhosis) diseases,
- Individuals who volunteered to participate in the study were included in the study.
Exclusion Criteria:
- Patients who have had their treatment postponed at least twice in a row,
- Those with a World Health Organization Oral Toxicity Scale score of 1 and above,
- Those who have received radiotherapy to the head and neck region,
- Those with head/neck, stomach and liver cancer,
- Those who cannot be reached during phone calls,
- Those whose chemotherapy protocol has changed or who will be applied to a protocol other than the specified agents,
- Those with neutropenia (neutrophils; 1000 mcL and below),
- Those with tooth sensitivity,
- Those who have experienced a change in taste before starting the chemotherapy protocol** and
- Those who do not want to continue the study will be excluded from the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention arm
Patients in this arm will receive oral cryotherapy.The patients in the intervention group will have ice applied to their mouths for three cycles (the first cycle they met with the researcher and the second and third cycles/an average of two months) when they come for treatment at the hospital with the researcher and at home on the days they do not come for treatment, within the scope of the oral cryotherapy application protocol, they will be monitored by phone and a reminder message will be sent.
During chemotherapy, ice cubes will be applied to the patients in the first hour they start receiving chemotherapy and in the same time period, three consecutive ice cubes (each ice cube melts for an average of 1.5-2 minutes/total average of 4.5-6 minutes) and the same application will be repeated three hours later.
The patients will be asked to apply ice cubes at home six times (an average of 27-36 minutes/day) at two or three hour intervals for seven days, including the day they receive che
|
The patients in the intervention group will have ice applied to their mouths for three cycles (the first cycle they met with the researcher and the second and third cycles/an average of two months) when they come for treatment at the hospital with the researcher and at home on the days they do not come for treatment, within the scope of the oral cryotherapy application protocol, they will be monitored by phone and a reminder message will be sent.
During chemotherapy, ice cubes will be applied to the patients in the first hour they start receiving chemotherapy and in the same time period, three consecutive ice cubes (each ice cube melts for an average of 1.5-2 minutes/total average of 4.5-6 minutes) and the same application will be repeated three hours later.
The patients will be asked to apply ice cubes at home six times (an average of 27-36 minutes/day) at two or three hour intervals for seven days, including the day they receive chemotherapy, and to record their applications on the "
Other Names:
|
|
No Intervention: Control arm
Patients who meet the study criteria and are included in the control group will receive routine treatment and care procedures in the unit when they come to receive chemotherapy (the first cycle encountered by the researcher) and the other two cycles that follow, and will not receive oral cryotherapy.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Chemotherapy-Induced Taste Alteration Scale (C-TAS)
Time Frame: two months
|
The scale was developed by Kano and Kanda in 2013.
The scale was developed to reveal the effects of chemotherapy-induced taste changes on the individual.
The validity and reliability study of the scale in Turkey was conducted by Sözeri and Kutlutürkan in 2014.
In the validity and reliability study, the Cronbach alpha value of the scale was found to be 0.86.
The scale consists of three subheadings, four subdimensions as "Reduction in the Perception of Basic Tastes", "Phantogeusia and Parageusia", "Discomfort" and "General Taste Changes" and a total of 18 items in a five-point Likert type (1-normal taste, 5-no taste).
The scores obtained from the scale subdimensions are used in the evaluation of the scores obtained from the scale.
The scores obtained from the scale subdimensions are obtained by summing up those items and dividing them by the number of items.
The maximum score that can be obtained from the subdimensions and the total scale score is five, while the minimum score is one.
|
two months
|
|
Simplified Nutritional Appetite Questionnaire (SNAQ)
Time Frame: two months
|
This questionnaire, which was developed in a simple and understandable way to measure the appetite of patients, was developed by Wilson et al. in 2005 and the Cronbach alpha value was found to be 0.70.
The validity and reliability of the questionnaire in Turkish was conducted by Tatar et al. in 2021 and the Cronbach alpha coefficient was found to be 0.86.
The scale consists of four questions and each question has five options (a = 1 point, b = 2 points, c = 3 points, d = 4 points, e = 5 points) and is scored between 4 and 20 points in total.
If the patient's score from the questionnaire is 14 points or less, this indicates that the individual is at risk for 5% weight loss in the last six months.
As the total score from the questionnaire decreases, the appetite level worsens.
|
two months
|
|
Malnutrition Universal Screening Tool (MUST)
Time Frame: two months
|
It is a five-step screening method recommended by the European Society of Parenteral and Enteral Nutrition (ESPEN) and the British Association for Parenteral and Enteral Nutrition (BAPEN).
The scale consists of three sections (malnutrition, malnutrition risk and obesity).
Malnutrition risk is classified as low, medium and high.
Scores from the categories of "Body Mass Index (BMI)", "Unexpected Body Weight Loss History" and "Acute Disease Effects" are used in the classification.
|
two months
|
|
European Organization for Research and Treatment of Cancer Qıality of Life Questionnaire (EORTC QLQ-30-Version 3.0)
Time Frame: two months
|
The EORTC QLQ-C30 was developed by the European Organization for Research and Treatment of Cancer in 1987 to assess the quality of life of cancer patients.
The scale was later revised by Aaronson et al. in 1993, and the Cronbach alpha coefficient was found to be 0.70.
The EORTC QLQ-C30 consists of three sub-dimensions, namely "general quality of life", "functional functions" (physical, role, cognitive, emotional, social) and "symptom scale" (fatigue, pain, nausea/vomiting, dyspnea, insomnia, anorexia, constipation, diarrhea, financial difficulties) and 30 questions.
The first 28 of the scale questions are of the four-point Likert type (not at all-1; very much-4).
High scores from the first 28 questions indicate low quality of life, while low scores indicate high quality of life.
The 29th and 30th questions of the scale are questions that constitute the general quality of life domain.
|
two months
|
|
Introductory information form
Time Frame: two months
|
This form prepared by the researchers includes three sections.
The first part includes eight questions about the sociodemographic characteristics of the patients (age, gender, marital status, employment status, etc.), the second part includes nine questions about the cancer disease and the treatment method applied (cancer type, stage, metastasis status, number of cures, chemotherapy regimen).
etc.) and the third part consists of a total of 31 questions, 13 of which include questions about taste changes, appetite and malnutrition (appetite status, oral care, etc.).
|
two months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Zeynep PEHLİVAN KÖKSAL, Masters, Recep Tayyip Erdogan University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- KTU-SBF-ZPK-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.